Leadership

A senior business development leader and visionary, Kent joined Allumiqs (formerly Proteoform Scientific) in 2018 to fully commercialize the company and lead strategic growth initiatives.

Kent brings more than 30 years of global experience in finance, operations, and business development to the company. With in-depth knowledge and hands-on experience in both start-up and high-growth organizations in Canada, the United States, Caribbean, and Latin America, Kent has a proven track record in accelerated business achievements.

Kent focuses on creating highly effective teams, expanding international markets, developing and nurturing key profitable business networks, and securing long-term client and partner relationships built on trust, which all contribute to successful business ventures.

Derek is our Chief Commercial Officer, accelerating organizational growth through solutions sales, marketing, analytics and forecasting, and portfolio strategy and planning. Joining Allumiqs in 2023, Derek brings strategic leadership experience in international business development, management, sales, and industry and vertical marketing to the team.

A seasoned IT business leader with over 30 years of experience in identifying key business opportunities and orchestrating resources to achieve success, Derek’s experience includes progressive commercial roles with Arcos Technologies (a Strategic Microsoft Solutions Partner), Microsoft, and IBM.

Hugo became the Chief Scientific Officer when Allumiqs was created in early 2022. Previously, he served as the CEO and co-founder of PhenoSwitch Bioscience, which was acquired by Proteoform Scientific to create Allumiqs.

During his Ph.D Hugo used mass spectrometry through different collaborations and core facility services to answer biological questions. He quickly learned that access to mass spectrometry was far from being simple and necessitates a considerable resource investment to obtain desirable results. Thus, PhenoSwitch Bioscience was founded, with a team of expert scientists, to address this specific need. Hugo studied at Université de Sherbrooke, where he earned a B.Sc. in biochemistry, M.Sc. in Pharmacology, and a Ph.D. in biochemistry.

Hugo has been the driving force behind the innovative LC-MS/MS services offerings and high-quality reputation the company has developed within the biotech, omics, and mass spec industries.

With over 18 years of experience leading globally-focused technology companies, Peter has worked with a number of large-scale clients including global, publicly traded firms and government organizations as well as smaller, privately-held companies. He was the CEO of Adaptiiv, co-founder of Oris4, and former CEO of Coemergence and director of a Hong Kong-based financial services firm.

Alan Doucette is internationally recognized as a leader in proteomics front-end sample preparation, particularly as it applies to the analysis of intact proteins by top-down MS.
He is credited with 35 peer-reviewed publications in the field of proteomics and analytical mass spectrometry and has made over 100 presentations at national and international scientific research conferences. He also has three patents and two license agreements for product commercialization. Since 2004, Alan has and continues to serve as a Professor of Chemistry at Dalhousie University. His program focuses on the development of advanced innovative technologies to improve advanced proteome characterization by mass spectrometry (MS).

Neil is an experienced surgeon and business leader with a demonstrated history in the healthcare industry. He has worked in both the private and public sector as a board chairman and executive chairman of a publicly traded company. Neil also has experience in transitioning companies from the private to public markets as well as raising capital, particularly for early stage start-ups in the biotech and life sciences space.

A senior business development leader and visionary, Kent joined Allumiqs (formerly Proteoform Scientific) in 2018 to fully commercialize the company and lead strategic growth initiatives.

Kent brings more than 30 years of global experience in finance, operations, and business development to the company. With in-depth knowledge and hands-on experience in both start-up and high-growth organizations in Canada, the United States, Caribbean, and Latin America, Kent has a proven track record in accelerated business achievements.

Kent focuses on creating highly effective teams, expanding international markets, developing and nurturing key profitable business networks, and securing long-term client and partner relationships built on trust, which all contribute to successful business ventures.

Hugo became the Chief Scientific Officer when Allumiqs was created in early 2022. Previously, he served as the CEO and co-founder of PhenoSwitch Bioscience, which was acquired by Proteoform Scientific to create Allumiqs.

During his Ph.D Hugo used mass spectrometry through different collaborations and core facility services to answer biological questions. He quickly learned that access to mass spectrometry was far from being simple and necessitates a considerable resource investment to obtain desirable results. Thus, PhenoSwitch Bioscience was founded, with a team of expert scientists, to address this specific need. Hugo studied at Université de Sherbrooke, where he earned a B.Sc. in biochemistry, M.Sc. in Pharmacology, and a Ph.D. in biochemistry.

Hugo has been the driving force behind the innovative LC-MS/MS services offerings and high-quality reputation the company has developed within the biotech, omics, and mass spec industries.